Delveinsight

AUGUST 6, 2020

Zydus starts phase 2 COVID-19 vaccine trial after clearing safety test. Zydus Cadila has finished a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 study. ZyCoV-D is designed to introduce DNA that encodes for a viral protein into human cells.

Allergies 53

Allergies Vaccination Vaccine Gene Therapy 53

Pfizer

JULY 26, 2022

Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. deliesschef. Tue, 07/26/2022 - 17:41.

Vaccination 111

Vaccination Vaccine Protein Immune Response 111

XTalks

NOVEMBER 6, 2020

Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The first healthy volunteer was dosed with the vaccine in Australia as part of the bacTRL-Spike COVID-19 Phase I clinical trial. Related: Red Meat Allergy Test Gets FDA Clearance. “We

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

pharmaphorum

SEPTEMBER 1, 2020

AstraZeneca has expanded development of COVID-19 vaccine AZD1222 into the US, beginning a phase 3 clinical trial across all adult age groups. The UK pharma said that the trial will recruit up to 30,000 adults aged 18 years or over to assess the safety, efficacy and immune response.

Vaccination 69

Vaccination Vaccine Trials Immune Response 69

Scienmag

MARCH 15, 2021

The first vaccine has been administered in a comparative adjuvant trial of DNA prime/protein boost HIV vaccine regimens in Kericho, Kenya Credit: U.S. Military HIV Research Program SILVER SPRING, Md.

Vaccination 68

Vaccination Vaccine Trials DNA 68

XTalks

SEPTEMBER 8, 2020

AZD1222 is now in Phase III clinical trials which will enroll approximately 30,000 adult volunteers in 80 states in the US, to determine whether the vaccine can help prevent symptomatic coronavirus disease from spreading. “Our AstraZeneca, a UK-based global pharmaceutical company, is leading the COVID-19 trial as a regulatory sponsor.

Manufacturing 83

Manufacturing Vaccination Vaccine Allergies 83

XTalks

AUGUST 22, 2023

It’s a grain-free breakfast cereal that contains only three grams of sugar and eight grams of plant-based protein. Its products are low in sugar, grain-free and enriched with protein. Through relentless trial and error, we landed on a formula that combines a lower sugar and higher protein ingredient standard with delicious flavor.”

Protein 98

Protein Branding Containment Production 98

XTalks

SEPTEMBER 21, 2023

announced that the first participant has been dosed in a new Phase I trial for an innovative HIV vaccine candidate, VIR-1388. The trial’s primary objective is to assess the safety of VIR-1388 and its capacity to stimulate a specific immune response against HIV in study participants. Vir Biotechnology, Inc.,

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

The Pharma Data

SEPTEMBER 1, 2020

AstraZeneca has started a Phase 3 trial of its experimental coronavirus vaccines in the US, making it the third company to start late-stage trials of a vaccine. . The trial will see participants receive either two doses of the vaccine or a placebo. Photo by Daniel Paquet from Regina, Canada. Conor Kavanagh. Source link.

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

XTalks

NOVEMBER 30, 2023

Its mechanism of action involves blocking the protein shell (capsid) of the HIV-1 virus, disrupting multiple crucial stages of the viral lifecycle. Both trials concluded with maintained virologic suppression, and no clinically significant change from baseline in CD4+ cell counts was observed. In addition, Vir Biotechnology, Inc.

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

Delveinsight

AUGUST 27, 2020

The phase 1 study that is being run by the National Institute of Allergy and Infectious Diseases tests three dose levels of the vaccine, mRNA-1273, given in two injections a month apart in 120 adults. The BET inhibitor worked by increasing beta-3 tubulin (TUBB3), a protein found in brain metastases.

Vaccination 53

Vaccination Vaccine Research Trials 53

The Pharma Data

MARCH 22, 2021

The AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalisation. The trial had a 2:1 randomisation of vaccine to placebo. The specific search for CVST found no events in this trial.

Trials 52

Trials Vaccination Vaccine Radiology 52

pharmaphorum

AUGUST 12, 2021

The results of the phase 1 trial suggest that antibodies could be used to protect travellers, military personnel and health care workers traveling to malaria-endemic regions, but also potentially to be used for seasonal control of the parasitic infection, according to the researchers.

Antibody 64

Antibody Vaccination Vaccine Allergies 64

Delveinsight

JANUARY 21, 2021

Drugs that target the cancer-promoting proteins MDM2 and BET have been attempted in acute myeloid leukaemia (AML) and have not been all that effective on their own. The combination appears to work by activation of the tumour-suppressing protein p53, they announced. The gene TP53 produces the protein p53, a known tumour suppressor.

Research 52

Research Protein Clinical Trials Clinical Trials 52

XTalks

JANUARY 20, 2021

However, IBS patients do not have allergies to any given foods, nor any gastrointestinal conditions, such as celiac disease. The mice were fed the protein again after the infection had been cleared, to see whether the infection had sensitized the immune system. Moreover, the response did not induce symptoms typical of a food allergy.

Immune Response 52

Immune Response Research Allergies Protein 52

The Pharma Data

JUNE 25, 2021

Nasdaq: NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% efficacy overall, and met the primary endpoint in its PREVENT-19 pivotal Phase 3 trial. Novavax, Inc. Government.” About PREVENT-19.

Vaccination 40

Vaccination Vaccine Trials Immune Response 40

The Pharma Data

JANUARY 24, 2021

With a presidential inauguration and a federal holiday, it wasn’t an enormously busy week for clinical trial news, but there was a fair amount, nonetheless. It inked a deal with the National Institute of Allergy and Infectious Diseases (NIAID) to launch a Phase I trial. Read on to see. COVID-19-Related. Non-COVID-19-Related.

Trials 52

Trials Allergies In-Vitro Antibody 52

XTalks

SEPTEMBER 16, 2024

HAE is caused by a deficiency or dysfunction of the C1-inhibitor, a protein involved in regulating inflammation. Cinryze, Haegarda) used to replace the deficient or dysfunctional C1 inhibitor protein in the blood, helping to prevent the inflammatory processes that cause angioedema.

Protein 52

Protein Genetics Trials Allergies 52

pharmaphorum

APRIL 28, 2021

The RNA interference (RNAi) drug is designed to treat haemophilia A and B patients by suppressing antithrombin (AT), a protein that inhibits blood clotting. Sanofi has since revised the dosing protocol for the fitusiran trials to a 50 mg dose administered every other month, which it thinks should keep most patients in the 15% to 35% AT range.

Drugs 52

Drugs Sales Allergies RNA 52

XTalks

JANUARY 27, 2021

The study was conducted in collaboration with the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH). “As The two variants studied have mutations in the spike protein of SARS-CoV-2, with 17 mutations in B.1.1.7 1.351 variant.

Vaccination 52

Vaccination Vaccine In-Vitro Protein 52

Scienmag

MAY 13, 2021

The new […].

Immune Response 53

Immune Response Antibody Protein Vaccination 53

The Pharma Data

MARCH 24, 2021

Positive high-level results from the primary analysis of the Phase III trial of AZD1222 in the US have confirmed vaccine efficacy consistent with the pre-specified interim analysis announced on Monday 22 March 2021. The NIAID-supported COVID-19 Prevention Network (CoVPN) participated in the trial. D8110C00001 1.

Vaccination 52

Vaccination Vaccine Radiology Trials 52

The Pharma Data

DECEMBER 17, 2020

The Moderna vaccine and the Pfizer-BioNTech vaccine use very similar technology, a piece of mRNA that codes for a segment of the coronavirus’s spike “S” protein. Both vaccines have demonstrated efficacy in clinical trials ranging from about 94 to 95%. The mRNA is encapsulated in a tiny fat molecule called a nanolipid particle.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

Pfizer

NOVEMBER 2, 2022

(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the advancement of an mRNA-based combination vaccine candidate for influenza and COVID-19 to a Phase 1 trial with the aim to address two severe respiratory diseases with one vaccine. Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) INDICATION. have a fever.

Vaccination 85

Vaccination Vaccine Clinical Trials Clinical Trials 85

The Pharma Data

MARCH 11, 2021

In this data set, the safety profile of bamlanivimab and etesevimab together was consistent with observations from other Phase 1, Phase 2 and Phase 3 trials evaluating these antibodies. Bamlanivimab is a recombinant, neutralizing human IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. Bamlanivimab alone.

Trials 40

Trials Antibody Medicine Development 40

XTalks

OCTOBER 26, 2023

This means COVID-19 can quickly produce viral proteins once inside the host cell, which may make its replication cycle faster than influenza. COVID-19 vaccines from Pfizer-BioNTech and Moderna are mRNA-based vaccines that encode for the spike protein located on the surface of the SARS-CoV-2 virus.

Vaccination 105

Vaccination Vaccine RNA Manufacturing 105

Pfizer

SEPTEMBER 28, 2022

This study is consistent with regulatory guidance and follows the design of the previous Phase 1/2/3 trial to evaluate further options for protection in this age group. . Monovalent refers to any authorized and approved COVID-19 vaccine that contains or encodes the spike protein of only the Original SARS-CoV-2 virus .

Vaccination 101

Vaccination Vaccine Medicine Clinical Trials 101

Pfizer

DECEMBER 8, 2022

Pfizer and BioNTech previously announced the start of a Phase 1 trial to examine the safety, tolerability, and immunogenicity of their combined influenza and COVID-19 candidate vaccine among healthy adults. . Tell your vaccination provider about all of your medical conditions, including if you: have any allergies. INDICATION.

Vaccination 81

Vaccination Vaccine Clinical Trials Clinical Trials 81

The Pharma Data

DECEMBER 14, 2020

Both vaccines have demonstrated about 94-95% efficacy in clinical trials. government’s Operation Warp Speed, Moderna has been working with the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID). Both use mRNA, which codes for a portion of the virus’s spike protein.

Vaccination 52

Vaccination Vaccine Allergies Genomics 52

The Pharma Data

JANUARY 6, 2021

A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures.’ In those earlier clinical trials, 88 men, women and children received a range of doses and a dose frequency up to 120 days with no adverse side effects. Bennett et al., ’ (2021) Viruses 13:52 [link].

Clinical Trials 40

Clinical Trials Clinical Trials Drugs In-Vitro 40

XTalks

DECEMBER 7, 2020

The Pfizer/BioNTech analysis was based on a trial involving some 43,000 volunteers in which investigators were able to show that there were 90 percent fewer infections among people who received two doses of the vaccine than among people who received placebo. New Treatments for COVID-19.

Vaccination 52

Vaccination Vaccine Development Drugs 52

The Pharma Data

DECEMBER 31, 2020

The messenger RNA (mRNA) vaccines encode a form of the spike (S) protein of SARS-CoV-2 virus. The vaccine teaches the cells to make a piece of the spike protein, which triggers an immune response to help prevent illness if later exposed to the virus. The partial piece of the spike protein cannot cause COVID-19 disease.

Vaccination 52

Vaccination Vaccine FDA Approval Hormones 52

The Pharma Data

FEBRUARY 12, 2022

” The data supporting this EUA are primarily based on analyses from the Phase 2 BLAZE-4 trial (NCT04634409), treatment arms 9-14. Lilly has licensed and developed bebtelovimab after it was discovered by AbCellera and the scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center.

Antibody 40

Antibody Trials Clinical Trials Clinical Trials 40

Bioengineer

JULY 23, 2021

“Given the respiratory tropism of the virus, it seems surprising that only seven of the nearly 100 SARS-CoV-2 vaccines currently in clinical trials are delivered intranasally,” Lund and Randall said. The seventh vaccine candidate is an inert protein subunit.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

Bioengineer

JULY 20, 2021

The FDA approval is based on the results of ProDERM (ClinicalTrials.gov Identifier: NCT02728752), a pivotal randomized clinical trial and the first study to evaluate the long term efficacy and safety of intravenous immunoglobulin (IVIg) for adults with dermatomyositis. residents. During the initial 16-week phase, 78.7%

FDA Approval 40

FDA Approval Clinical Trials Clinical Trials Trials 40

The Pharma Data

JANUARY 26, 2021

“Notably, the 70 percent decrease in risk of hospitalizations or death seen in this Phase 3 trial of bamlanivimab and etesevimab together is consistent with the reduction in risk of hospitalization or ER visits seen with bamlanivimab alone in the Phase 2 trial. INDIANAPOLIS, Jan. Across 1,035 patients, there were 11 events (2.1

Antibody 52

Antibody Trials Clinical Trials Clinical Trials 52

Pfizer

JANUARY 27, 2023

Working with collaborators, we have conducted research where the original SARS-CoV-2 virus has been used to express the spike protein from new variants of concern. In the ongoing development of the Pfizer-BioNTech COVID-19 vaccine, Pfizer has not conducted gain of function or directed evolution research.

Research 112

Research Vaccination Vaccine Drugs 112